The estimated Net Worth of Kenneth Greathouse is at least $30.4 Tisíc dollars as of 23 November 2021. Mr. Greathouse owns over 10,000 units of Zosano Pharma Corp stock worth over $24,360 and over the last 7 years he sold ZSAN stock worth over $6,000. In addition, he makes $0 as Independent Director at Zosano Pharma Corp.
Kenneth has made over 4 trades of the Zosano Pharma Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of ZSAN stock worth $6,000 on 23 November 2021.
The largest trade he's ever made was buying 95,000 units of Zosano Pharma Corp stock on 30 November 2017 worth over $58,900. On average, Kenneth trades about 17,500 units every 123 days since 2017. As of 23 November 2021 he still owns at least 43,500 units of Zosano Pharma Corp stock.
You can see the complete history of Mr. Greathouse stock trades at the bottom of the page.
Kenneth R. Greathouse is Independent Director of the Company. Kenneth R. Greathouse is a seasoned pharmaceutical executive with over 40 years of experience in sales, marketing, business development and commercial operations. He is the co-founder of several successful drug development companies, including Manchester Pharmaceuticals which was sold to Retrophin Inc. in 2014. He began his career with Lederle Laboratories where for over 18 years he held a number of sales and marketing positions of increasing responsibility. He joined Athena Neurosciences in 1993 and continued with Elan Pharmaceuticals after the acquisition of Athena. After a two year tenure at Boron LePore and Associates as Vice President and General Manager of Contract Sales, he joined Questcor as Senior Vice President, Commercial Operations. Since leaving Questcor, Mr. Greathouse has co-founded and served as CEO of Argent Development Group LLC, Melbourne Laboratories LLC, Valcrest Pharmaceuticals LLC, and Hesperian BioPharma LLC, in addition to Manchester Pharmaceuticals LLC.
Kenneth's mailing address filed with the SEC is C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT, CA, 94555.
Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L... a Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Zosano Pharma Corp executives and other stock owners filed with the SEC include: